CCL20 expression is also upregulated in tumour cells isolated from melanoma, breast cancer, colon carcinoma and head and neck squamous cell carcinoma (HNSCC) patients, in conjunction with activation of the EGFR/Ras-signalling pathway. Here, CCL20 is linked to neoplasm.